- Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up
-
Cahilog C, Danguilan R, David PM, Arakama MH, Pamugas GE
- KMID: 2509195
- Korean J Transplant.
- 2020 Dec;34(Supple 1):S53.
- doi: 10.4285/ATW2020.OP-1026
Background: Kidney transplantation has significantly improved survival and quality of life of patients with end-stage renal disease and is considered the best form of renal replacement therapy. Rabbit anti-thymocyte globulin... -
- CITED
-
- Close
- SHARE
-
- Close
